Darmstadt, Germany (ots/PRNewswire) - - New data builds on company's longstanding commitment to MS Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 3rd Congress of the European Academy of Neurology (EAN), taking place from June 24-27, in Amsterdam, ...
Darmstadt, Germany (ots/PRNewswire) - - Efficacy and safety data support positive benefit/risk assessment from CHMP - Cladribine Tablets is the first and only investigational medicinal product to have shown a sustained 4 years of disease control with a maximum of 20 days of oral treatment over 2 years in clinical ...
Geneva (ots/PRNewswire) - Leading specialists at ICPIC congress come together to discuss the issue of SSIs and recent guidelines regarding the use of triclosan-coated sutures in all types of surgery[6] Ethicon* part of the Johnson & Johnson Medical Devices Companies** has joined leading wound closure specialists to discuss recommendations to ease the burden of surgical site infections (SSIs) on patients and costs to ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding disorder[1],[2],[3] Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare ...
Craigavon, N.I., UK, Lausanne, Switzerland (ots) - Almac Discovery (www.almacgroup.com/discovery), a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA (Debiopharm - www.debiopharm.com), a Switzerland based specialty ...
Sunnyvale, California (ots/PRNewswire) - The French Cancer Institute is Building its Re-irradiation and Adaptive Radiotherapy Program Using the Latest Technology Developed by Accuray Accuray Incorporated (NASDAQ: ARAY) announced today that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) is providing advanced radiation treatments to cancer patients ...
Hørsholm, Denmark (ots/PRNewswire) - - Allergic rhinitis has a major impact on children's quality of life - Children with allergic rhinitis have an increased risk of developing asthma - Early treatment may prevent asthma symptoms In a symposium sponsored by ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), leading ...
Luxembourg, and Ness Ziona, Israel (ots) - - Cross reference: Picture is available at http://www.presseportal.de/pm/127019/3664051 - The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd., developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a EUR20 million loan ...
Lausanne (ots) - A total of 96 patients randomized in France and Switzerland. Results expected in Q1 2019. Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the completion of enrollment in dose finding and ...
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13[1], which plays an important role in the development of moderate-to-severe atopic dermatitis[2]. Tralokinumab is not ...
Madrid (ots/PRNewswire) - Sirukumab Phase 3 Data Presented at the Annual European Congress of Rheumatology (EULAR) 2017 also Show Significant Improvement in Quality of Life Measures Janssen-Cilag International NV (Janssen) today announced long-term results from SIRROUND-T*, a pivotal Phase 3 study that showed ...
Bagsværd, Denmark (ots/PRNewswire) - Findings from a post hoc analysis of the LEADER cardiovascular (CV) outcomes trial showed that treatment with Victoza® (liraglutide) resulted in similar reductions in the risk of major cardiovascular events in people with type 2 diabetes at high CV risk, regardless of whether ...
San Diego (ots/PRNewswire) - Symposium: 3-CT-SY22 Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100, in adults with type 2 ...
Bagsværd, Denmark (ots/PRNewswire) - Poster Presentations #999-P, #1010-P, #1014-P Findings from the real-world study, EU-TREAT (EUropean TREsiba AudiT), were presented today at the American Diabetes Association's 77th Scientific Sessions (ADA) in San Diego, US. The study showed that people with type 1 diabetes and ...
Johnson & Johnson Medical GmbH
Norderstedt, Germany (ots/PRNewswire) - Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) - ...
Québec, Canada and Lausanne, Switzerland (ots) - GenePOC announces it received 510(k) clearance from the US Food and Drug Administration to market its first molecular assay to detect Group B Streptococcus and for the revogene molecular diagnostics instrument. GenePOC, Inc. (GenePOC) a member of the Debiopharm Group is pleased to announce that it has received FDA ...
Amsterdam (ots/PRNewswire) - Proceedings of the National Academy of Science (PNAS) paper* details results of a pre-clinical study into the combined use of drug-loaded temperature sensitive liposomes and MR-HIFU for local tumor treatment. Royal Philips (http://www.philips.com) (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the publication of a ...
Lausanne, Switzerland (ots) - Debio 1347/CH5183284 was evaluated in patients with FGFR genomically activated advanced solid tumors Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced the results from the phase I ...
Calgary, Alberta (ots/PRNewswire) - The symposium titled: "Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?" at the ERA-EDTA Congress highlights BET-inhibition and apabetalone in addressing the significant unmet medical need in chronic kidney disease and cardiovascular disease. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced ...
Darmstadt, Germany (ots/PRNewswire) - - Preliminary research indicates most MS carers are between the ages of 18-34, the prime of their lives - Largest global MS carer survey with International Alliance of Carer Organizations (IACO) to help identify unmet needs and social impact Merck, a leading science and technology company, honors World MS Day 2017 by announcing a ...
Calgary, Alberta (ots/PRNewswire) - Apabetalone expands in to first orphan disease clinical trial in patients with Fabry disease Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical ...
Edmonton, Alberta (ots/PRNewswire) - OncoQuest Inc. ("OncoQuest"), a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, today announced the presentation of initial safety and efficacy data from the company's ...
Lausanne, Switzerland and Waltham, Mass. (ots) - Transaction adds innovative clinical-stage program to expanding Debiopharm portfolio and broadens its clinical development expertise Divestiture aligns with ImmunoGen's focus on strategic growth initiatives and generates near-term value Debiopharm International SA ...
Calgary, Alberta (ots/PRNewswire) - Nature Reviews Nephrology and Pfizer Inc. discuss BET bromodomain inhibition and apabetalone as viable drug candidates Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today highlighted two additional works involving its lead drug, apabetalone, one recently published ...
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
Lyon, France and Boston (ots/PRNewswire) - Mérieux Développement has recently concluded an equity investment into Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on the development and commercialization of novel formulations of injectable drugs. With this additional financing, Xeris Pharmaceuticals expects to fund registration trials and ...
Shire Pharmaceuticals Group Plc
Zug, Switzerland (ots/PRNewswire) - New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, announced today new research to be presented on rhPTH(1-84) and on the ...
National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI)
Singapore (ots/PRNewswire) - The SIRveNIB abstract published on-line in the Journal of Clinical Oncology states that treatment of locally advanced Hepatocellular Carcinoma (HCC) with a single treatment of SIR-Spheres® Y-90 resin microspheres results in Overall Survival not significantly different from twice-daily ...
Shire Pharmaceuticals Group Plc
Dublin (ots/PRNewswire) - - Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to placebo in three of four tested dose groups - First study to investigate the potential role of anti-MAdCAM antibody in the management of ...